Investing.com – Capricor Therapeutics (NASDAQ: )’s third-quarter report beat analyst expectations. The report was released on Tuesday and the company reported revenues that beat expectations.
Earnings per share reached $-0.250 while revenue was $6.19M. Market opinion polls from Investing.com indicated an expected earnings per share of $-0.300 and company profits of $3.15M. Also, in terms of the last quarter
Capricor Therapeutics shares gained 6.31% to trade at $3,200 after hours, according to the report.
During the year, Capricor Therapeutics shares traded down 22%, underperforming the Nasdaq which is up 34.66% over the current year.
Capricor Therapeutics stock is tracking Sector profits health care The other one is this the month
On Day 2, Lilly, Eli & Co. reported Q3 with quarterly EPS of $0.1 on revenue of $9.5B, compared to expectations of $-0.2 EPS on revenue of $8.97B.
Novo Nordisk ADR’s earnings exceeded analysts’ expectations on Day 2, during the third quarter, with quarterly earnings per share of $5 and revenues of $58.73B. Investing.com analysts also expected profits of $0.6751 and revenues of $8.16B.
2023-11-14 21:12:00
#Capricor #Therapeutics #Earnings #Revenue #Beat #Expectations #Investing.com
